ICICI Direct's research report on Shalby
Q2FY21 results were better than expectations on all fronts. Revenues grew 201% QoQ to Rs 115.6 crore (Rs 38.4 crore in Q1FY21) on the back of a revival in patient footfalls, higher surgeries count, better occupancy. EBITDA margins were at 25.5% vs. -12.6% in Q1 due to better overall operational performance QoQ stemming from cost rationalisation measures. Hence, Shalby posted EBITDA of Rs 29.5 crore (vs. EBITDA loss of Rs 4.8 crore in Q1). PAT for the quarter was at Rs 24.5 crore vs. a loss of Rs 8.7 crore in Q1FY21.
Outlook
However, skewed margins, weak return ratios still remain major deflators. We arrive at a target price of Rs 100 based on SOTP by valuing hospitals (above six years) at 8x FY23E EV/EBITDA and hospitals (below six years) at 1x FY23E EV/sales.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.